致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 密迪斯肌控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08307 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD 10,00 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08307 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 396,736,000 | | 0 | | 396,736,000 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | | 396,736,000 | | 0 | | 396,736,000 | 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 ...

Company Overview - Medicskin Holdings Limited is a Hong Kong investment holding company primarily providing medical skin care services, founded by Dr. Jiang in 2000 [2] - The company operates two Medicskin centers in Hong Kong, focusing on treating skin diseases and improving appearance [2] - Services offered include treatment for acne, pigmentation, rosacea, eczema, warts, and aesthetic procedures such as skin rejuvenation and contouring [2] Financial Performance - As of September 30, 2025, Medicskin reported total revenue of HKD 20.79 million, a year-on-year increase of 1.97% [1] - The net profit attributable to shareholders was HKD 32,000, reflecting a significant year-on-year growth of 101.72% [1][3] - The gross profit margin stood at 81.58%, while the debt-to-asset ratio was 91.54% [1] Market Position and Valuation - Medicskin's current price-to-earnings (P/E) ratio is -40.01, ranking 77th in its industry, compared to the average P/E ratio of 4.68 for other healthcare companies [1] - Other companies in the healthcare sector have P/E ratios such as Jingjiu Kangliao at 1.53, Yihui Group at 2.84, and Global Medical at 5.54 [1] Stock Performance - As of November 28, the Hang Seng Index fell by 0.34%, while Medicskin's stock price increased by 12.12% to HKD 0.148 per share, with a trading volume of 8,000 shares [1] - Over the past month, Medicskin's stock has declined by 32.65%, and year-to-date, it has decreased by 12%, underperforming the Hang Seng Index's increase of 29.34% [1] Institutional Ratings - Currently, there are no investment rating recommendations from institutions for Medicskin [1]

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：8307） NOTIFICATION LETTER 通知信函 28 November 2025 Dear Registered Shareholder, Should you have any queries relating to this notification, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). By order of the Board Medicskin Holdings Limited Dr. Kong Kwok Leung Chairman and Executive Director Notes: 各位登記股東： 密迪斯肌控股有限公司（「本 ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） Dear Non-Registered Holder(Note 1) , Medicskin Holdings Limited (the "Company") - Notice of publication of 2025/26 Interim Report ("Current Corporate Communication") on the Company's website The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.medicskinholdings.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkex ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 22,774,000, representing a 1.98% increase from HKD 22,334,000 in the same period of 2024[4] - The company reported a pre-tax profit of HKD 35,000 compared to a pre-tax loss of HKD 2,038,000 in the previous year, indicating a significant turnaround[4] - Basic earnings per share improved to HKD 0.01 from a loss of HKD 0.51 per share in the prior year[5] - Total comprehensive income for the period was HKD 36,000, compared to a loss of HKD 2,048,000 in the same period last year[4] - The pre-tax profit for the six months ended September 30, 2025, was HKD 11,238,000, a decrease of 7.8% from HKD 12,188,000 in 2024[21] - The group recorded a profit attributable to the owners of the company of HKD 35,000 for the six months ended September 30, 2025, compared to a loss of HKD 2.0 million for the same period in 2024[41] Assets and Liabilities - Non-current assets decreased to HKD 19,098,000 from HKD 20,298,000 as of March 31, 2025[6] - Current assets decreased to HKD 30,905,000 from HKD 37,145,000, primarily due to a reduction in cash and cash equivalents[6] - The company’s total liabilities decreased from HKD 43,313,000 to HKD 38,754,000, reflecting improved financial stability[6] - The group reported a net current liability of HKD 7,849,000 as of September 30, 2025, primarily due to contract liabilities amounting to HKD 20,897,000[13] - The group’s total equity as of September 30, 2025, was HKD 4.2 million, unchanged from March 31, 2025[53] - The group’s debt-to-asset ratio as of September 30, 2025, was 39.8%, slightly up from 39.7% on March 31, 2025[54] Cash Flow - Cash used in operating activities was HKD 1,372,000, a decline from cash generated of HKD 982,000 in the previous year[8] - The company incurred a net cash outflow of HKD 4,853,000 in the six months ended September 30, 2025, compared to an inflow of HKD 6,017,000 in the same period last year[8] - The group expects to generate sufficient cash flow in the next twelve months to meet its obligations, with available undrawn bank loan facilities of HKD 18,000,000[13] Revenue Breakdown - The revenue breakdown includes HKD 462,000 from medical consultation services, HKD 3,797,000 from prescription and dispensing services, and HKD 18,515,000 from treatment services[16] - The group's revenue for the six months ended September 30, 2025, increased by approximately HKD 0.4 million or 2.0% to HKD 22.8 million, compared to HKD 22.3 million for the same period in 2024[43] - The number of customers for treatment services increased, contributing to the revenue growth[43] Other Income and Expenses - Other income for the six months ended September 30, 2025, totaled HKD 797,000, compared to HKD 634,000 for the same period in 2024, reflecting an increase of 25.8%[20] - Employee costs decreased by approximately HKD 1.0 million or 7.8% to HKD 11.2 million for the six months ended September 30, 2025[46] - Depreciation of right-of-use assets decreased by approximately HKD 1.0 million or 26.9% to HKD 2.7 million for the six months ended September 30, 2025, due to reduced rental expenses[47] Share Capital and Dividends - The company has maintained its share capital at HKD 3,967,000 with reserves increasing to HKD 264,000 from HKD 228,000[6] - The total number of issued shares remained at 396,736,000 as of September 30, 2025, with a par value of HKD 0.01 per share[33] - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with 2024[25] Strategic Initiatives - The company’s management discussed the strategic positioning of its Medicskin and facematter brands, focusing on medical skin care and aesthetic treatments[38] - The group plans to enhance resilience and competitiveness by continuing operational optimization and improving marketing strategies[42] - The group aims to expand brand awareness and identify new business opportunities through strategic initiatives[42] Market Environment - The global business environment remains uncertain due to geopolitical tensions and high tariffs imposed by the U.S., impacting business confidence in Hong Kong[39] - The company’s management noted a shift in consumer behavior, with local residents increasingly opting for overseas travel and spending in the Greater Bay Area, affecting local market consumption[39] Share Option Scheme - The company has adopted a new share option scheme on September 27, 2024, allowing eligible employees to subscribe for shares[62] - The old share option scheme was terminated at the annual general meeting held on September 27, 2024[74] - The new share option plan has been approved by shareholders at the 2024 Annual General Meeting to attract and retain top talent, effective from September 27, 2024, for a duration of 10 years[75] - No share options were granted, exercised, vested, lapsed, or cancelled for the six months ending September 30, 2025[76] - The new share option plan allows for the grant of options involving 39,673,600 shares and 7,934,720 shares under specific limits for service providers[76] - The remaining term of the new share option plan is approximately 9 years[76] Governance and Compliance - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited interim financial statements for the six months ending September 30, 2025, ensuring compliance with applicable accounting standards and GEM listing rules[77]

Core Viewpoint - The company reported a revenue of HKD 22.774 million for the six months ending September 30, 2025, representing a year-on-year increase of 1.97% [1] - The company achieved a profit attributable to owners of HKD 0.035 million, a turnaround from a loss of HKD 2.033 million in the same period last year, indicating a significant improvement in financial performance [1] - Earnings per share were reported at HKD 0.0001 [1] Financial Performance - Revenue for the period was HKD 22.774 million, up 1.97% year-on-year [1] - The company turned a profit of HKD 0.035 million compared to a loss of HKD 2.033 million in the previous year [1] - Earnings per share increased to HKD 0.0001 [1] Cost Management - The turnaround from loss to profit was primarily attributed to cost savings from the depreciation of right-of-use assets due to reduced rental expenses, amounting to approximately HKD 1 million [1] - Additionally, savings in employee costs also contributed to the improved financial results, with a similar impact of around HKD 1 million [1]

Core Viewpoint - The company reported a revenue of HKD 22.774 million for the six months ending September 30, 2025, representing a year-on-year increase of 1.97% [1] - The company achieved a profit attributable to owners of HKD 3.5 million, a turnaround from a loss of HKD 2.033 million in the same period last year, indicating a significant improvement in financial performance [1] - Earnings per share were reported at HKD 0.01 [1] Financial Performance - Revenue for the period was HKD 22.774 million, up 1.97% year-on-year [1] - The company transitioned from a loss of HKD 2.033 million to a profit of HKD 3.5 million, marking a notable recovery [1] - Earnings per share increased to HKD 0.01 [1] Cost Management - The turnaround from loss to profit was primarily attributed to cost savings from the depreciation of right-of-use assets due to reduced rental expenses, amounting to approximately HKD 1 million [1] - Additionally, savings in employee costs contributed to the improved financial results, also around HKD 1 million [1]

Financial Performance - The company's revenue for the six months ended September 30, 2025, was HKD 22,774,000, representing an increase of 1.98% compared to HKD 22,334,000 for the same period in 2024[6] - The company reported a pre-tax profit of HKD 35,000, a significant recovery from a loss of HKD 2,038,000 in the previous year[6] - The net profit attributable to the owners of the company was HKD 35,000, compared to a loss of HKD 2,033,000 in the same period last year[7] - The total comprehensive income for the period was HKD 36,000, recovering from a loss of HKD 2,048,000 in the previous year[7] - For the six months ended September 30, 2025, the company reported a total comprehensive income of HKD 36,000, which includes a profit of HKD 35,000[9] - Profit before tax for the six months ended September 30, 2025, was HKD 35,000, a significant improvement from a loss of HKD 2,033,000 in 2024[27] - The group recorded a profit attributable to owners of the company of HKD 35,000 for the six months ended September 30, 2025, compared to a loss of HKD 2.0 million for the same period in 2024[43] Revenue Breakdown - Revenue from medical consultation services decreased to HKD 462,000 from HKD 535,000 year-over-year[18] - Revenue from prescription and dispensing services decreased to HKD 3,797,000 from HKD 4,112,000 year-over-year[18] - Revenue from treatment services increased to HKD 18,515,000 from HKD 17,687,000 year-over-year[18] - The revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.0%, 16.7%, and 81.3% of total revenue, respectively[42] Assets and Liabilities - The company's total assets decreased to HKD 50,003,000 as of September 30, 2025, down from HKD 57,443,000 as of March 31, 2025[8] - Current liabilities decreased to HKD 38,754,000 from HKD 43,313,000, indicating improved liquidity management[8] - The company's cash and cash equivalents decreased to HKD 12,492,000 from HKD 17,344,000, reflecting a reduction in available cash[8] - As of September 30, 2025, the company had a net current liability of HKD 7,849,000, primarily due to contract liabilities of HKD 20,897,000[15] - The net current liabilities of the group were HKD 7.8 million as of September 30, 2025, compared to HKD 6.2 million as of March 31, 2025[55] - The group's debt-to-asset ratio was 39.8% as of September 30, 2025, slightly up from 39.7% as of March 31, 2025[56] Cash Flow - The company generated a net cash outflow from operating activities of HKD 1,372,000 for the six months ended September 30, 2025, compared to a cash inflow of HKD 982,000 in the same period of 2024[10] - The company recorded a net decrease in cash and cash equivalents of HKD 4,853,000 for the six months ended September 30, 2025[10] - The group's bank balance and cash amounted to HKD 12.5 million as of September 30, 2025, down from HKD 17.3 million as of March 31, 2024[55] Employee and Management Costs - Employee costs decreased by approximately HKD 1.0 million or 7.8% to HKD 11.2 million for the six months ended September 30, 2025, down from HKD 12.2 million for the same period in 2024[48] - Total compensation for key management personnel for the six months ended September 30, 2025, was HKD 4,490,000, down from HKD 5,297,000 in 2024[38] - The group employed 28 full-time and 13 part-time employees as of September 30, 2025, compared to 27 full-time and 16 part-time employees as of March 31, 2025[64] Future Outlook and Strategy - The company has not provided specific guidance for future performance but indicated a focus on improving operational efficiency and exploring market expansion opportunities[6] - The group aims to enhance resilience and competitiveness by implementing operational optimization measures and improving marketing strategies to strengthen customer loyalty and engagement[44] - The group plans to continue focusing on non-surgical, non-invasive, and minimally invasive medical beauty treatments, which are seeing increasing demand[44] Dividends and Share Options - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with the previous year[27] - The board did not recommend the payment of an interim dividend for the six months ended September 30, 2025[54] - The new share option plan, effective from September 27, 2024, is designed to attract and retain top talent, providing eligible participants with opportunities for personal equity ownership[77] - No share options were granted, exercised, vested, lapsed, or cancelled during the six months ending September 30, 2025[78] Compliance and Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the interim financial statements for the six months ending September 30, 2025, confirming compliance with applicable accounting standards and GEM listing rules[79] - The company has adopted a code of conduct for securities trading by directors and employees, with no known violations during the six months ending September 30, 2025[73] - The board of directors is committed to maintaining a positive relationship among its members and ensuring that the board's actions align with the company's best interests[72] - The company is led by Dr. Jiang, who serves as both the chairman and CEO, overseeing overall operations and business strategies[72]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 密迪斯肌控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08307 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD 10,0 ...